A comprehensive insight on the recent development of Cyclic Dependent Kinase inhibitors as anticancer agents

Area of Science:

• Oncology
• Molecular Biology
• Drug Discovery

Background:

• Cancer remains a leading global cause of death despite advances in anticancer drug development.
• Cyclin-Dependent Kinase (CDK)-Cyclin complexes are vital regulators of cellular processes, including cell cycle, gene transcription, and DNA repair.
• Deregulation and overexpression of CDKs contribute to uncontrolled tumor cell proliferation, making them attractive therapeutic targets.

Purpose of the Study:

• To review recent advancements in the development of Cyclin-Dependent Kinase (CDK) inhibitors for cancer therapy.
• To provide insights into the structure-activity relationships (SAR) of these inhibitors.
• To discuss the molecular docking and mechanisms of action of novel CDK inhibitors.

Main Methods:

• Literature review of recent scientific publications on CDK inhibitors.
• Analysis of structure-activity relationships based on published data.
• Summary of molecular docking studies and proposed mechanisms of action.

Main Results:

• Several novel CDK inhibitors have been developed, showing promising efficacy in preclinical studies.
• Structure-activity relationship studies have identified key molecular features for potent and selective CDK inhibition.
• Molecular docking and mechanistic studies elucidate how these inhibitors interact with CDK targets.

Conclusions:

• Cyclin-Dependent Kinase inhibitors represent a credible and evolving strategy for cancer treatment.
• Understanding SAR and molecular interactions is key to designing more effective and targeted anticancer therapies.
• Continued research into CDK inhibitors holds significant potential for overcoming cancer cell proliferation.